Please login to the form below

Not currently logged in

Chris Molloy is new head of RSA

Life sciences executive search and interim management specialist RSA has appointed a new chief executive

RSA Chris MolloyChris Molloy, a non-executive director at RSA since 2009, joins RSA in a full-time capacity from IDBS, where he was VP, corporate development and marketing.

Molloy brings with him more than 20 years' experience in life sciences, spanning the pharmaceuticals, biotechnology and start-up sectors.

He started out with Glaxo, where he held a range of management, research, business change and scientific collaboration roles through the company's merger to become GlaxoSmithKline (GSK), before moving to Asia in 2004 as chief operating officer of emerging biotech firm MerLion Pharmaceuticals.

In addition to taking over as CEO at RSA, Molloy will retain his active scientific role in the pre-clinical development and licensing of new medicines for HIV with KFLP Biotech, a 'virtual' US R&D company.

“We are excited to have Chris on board as RSA's CEO. He will continue to preserve the special culture and feel of RSA whilst making us even more professional as an executive search and interim business,” said executive chairman Nick Stephens.

11th September 2013

From: Sales, Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...